Xcout Intel
iOmx Therapeutics
iOmx Therapeutics AG is a biopharmaceutical company located in Martinsried near Munich, Germany, dedicated to discovering and developing next-generation targeted cancer immunotherapies.
Subscribe to see iOmx Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
iOmx Therapeutics at a glance
iOmx Therapeutics is a biotechnology company headquartered in Germany. It has raised at least $122.5M across the 2 funding rounds on record. Its most recent funding round, Series B, raised $75.4M in October 2021. Xcout tracks 11 named people at iOmx Therapeutics, including Apollon Papadimitriou (Chief Executive Officer).
iOmx Therapeutics leadership
- Apollon PapadimitriouChief Executive Officer
- Rüdiger WolffChief Financial Officer
- Christine RotheChief Development Officer
- Hannes LofererChief Operations Officer
- Tiantom JarutatChief Medical Officer
- Gerald H. MoellerChairman of the Supervisory Board
5 more named people on record for iOmx Therapeutics, with roles, board committees and tenure — see the full roster →
iOmx Therapeutics funding rounds
At least $122.5M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $75.4M | 7 named | |
| Series A | $47.1M | 3 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
iOmx Therapeutics competitors
A few of iOmx Therapeutics's closest competitors — see the full list of competitors and alternatives →
Immatics is a biopharmaceutical company that develops T cell-based immunotherapies and bispecific product candidates to treat various types of cancer. The company focuses on precision targeting of the PRAME protein expressed in multiple solid tumors, serving cancer patients with high unmet medical needs.
ImmunOs Therapeutics AG is a biotechnology company that develops treatments for cancer and inflammatory diseases by harnessing the human immune system. The company focuses on immuno-oncology and autoimmune therapies through a dedicated drug pipeline.
ImmPACT Bio is a biotechnology company developing next-generation cancer immunotherapies, including dual-targeted CAR T-cell therapies. Its programs are intended to serve patients with B-cell malignancies and potentially other cancers, including solid tumors.
T3 Pharmaceuticals AG is a biotechnology company that develops a proprietary technology platform utilizing bacteria to deliver targeted therapies. The company focuses on advancing a pipeline of Immuno-Oncology products designed to treat cancer patients.
ImmuXell Biotechnology is a clinical-stage biopharmaceutical innovation company headquartered in Shanghai, China. Founded in 2021, the company focuses on developing novel immune cell therapies targeted at treating solid tumor cancers.
Immunomic Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company founded in 2005 and headquartered in Rockville, Maryland, that develops innovative immune therapies.
Get iOmx Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on iOmx Therapeutics in Xcout Intel
- 11 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access